PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and ne ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

As part of the collaboration, Secarna will leverage its proprietary, AI-empowered OligoCreator® discovery and development platform to identify promising oligonucleotide candidates, applying both ...

September 30, 2025 -- VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, ...

Can you share some highlights from the BETTER study with us? Marion Munk, MD, PhD: I'm very excited about this project. We ...

Oligonucleotide (oligo) therapies are gaining momentum due to their broad applications in diagnostics, therapeutics, research, and personalized medicine. These treatments offer precise, ...

PepGen Inc. ( ($PEPG) ) just unveiled an update. On September 24, 2025, PepGen Inc. announced an underwriting agreement with Leerink Partners LLC ...

PepGen Inc. ( ($PEPG) ) has issued an announcement. On September 24, 2025, PepGen Inc. announced positive results from its FREEDOM-DM1 Phase 1 ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide ...

Sandun Fernando, Ph.D., has been named a Fellow of the American Society of Agricultural and Biological Engineers.

By improving gait stability, Ionis’ zilganersen could be “potentially disease modifying,” according to analysts at William ...

Angelini Pharma secures exclusive option to license global development and commercialization rights for SVG1051, a pre-clinical investigational ...